These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 28593685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y, OBSERV-IBD study group, the GETAID.
    Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
    Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.
    Inflamm Bowel Dis; 2018 Mar 19; 24(4):849-860. PubMed ID: 29562271
    [Abstract] [Full Text] [Related]

  • 5. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J.
    Scand J Gastroenterol; 2017 Mar 19; 52(6-7):722-729. PubMed ID: 28362144
    [Abstract] [Full Text] [Related]

  • 6. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC.
    Inflamm Bowel Dis; 2016 Sep 19; 22(9):2121-6. PubMed ID: 27542130
    [Abstract] [Full Text] [Related]

  • 7. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA.
    J Crohns Colitis; 2016 Apr 19; 10(4):402-9. PubMed ID: 26681763
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I.
    Inflamm Bowel Dis; 2017 Mar 19; 23(3):404-408. PubMed ID: 28178003
    [Abstract] [Full Text] [Related]

  • 9. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
    Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W.
    Eur J Intern Med; 2019 Aug 19; 66():85-91. PubMed ID: 31208827
    [Abstract] [Full Text] [Related]

  • 10. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.
    BMC Gastroenterol; 2018 Sep 15; 18(1):140. PubMed ID: 30219028
    [Abstract] [Full Text] [Related]

  • 11. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.
    Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany Consortium.
    Aliment Pharmacol Ther; 2016 May 15; 43(10):1090-102. PubMed ID: 27038247
    [Abstract] [Full Text] [Related]

  • 12. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, GETECCU study group.
    Aliment Pharmacol Ther; 2018 Oct 15; 48(8):839-851. PubMed ID: 30281832
    [Abstract] [Full Text] [Related]

  • 13. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
    Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes AC, Nones RB, Teixeira FV, Zeroncio M, Kotze PG.
    Arq Gastroenterol; 2019 Oct 15; 56(3):312-317. PubMed ID: 31633731
    [Abstract] [Full Text] [Related]

  • 14. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb 15; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.
    Inflamm Bowel Dis; 2018 Oct 12; 24(11):2442-2451. PubMed ID: 29788318
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
    Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V.
    Inflamm Bowel Dis; 2015 Dec 12; 21(12):2879-85. PubMed ID: 26288002
    [Abstract] [Full Text] [Related]

  • 17. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
    Aliment Pharmacol Ther; 2016 Dec 12; 44(11-12):1199-1212. PubMed ID: 27714831
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J.
    Eur J Pediatr; 2021 Sep 12; 180(9):3029-3038. PubMed ID: 33880650
    [Abstract] [Full Text] [Related]

  • 19. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW.
    J Crohns Colitis; 2019 Sep 19; 13(9):1111-1120. PubMed ID: 30768123
    [Abstract] [Full Text] [Related]

  • 20. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
    Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, Feagan BG.
    Inflamm Bowel Dis; 2013 Jul 19; 19(8):1691-9. PubMed ID: 23591599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.